Skip to main content
NCBI home page
Indian Journal of Psychiatry logoLink to Indian Journal of Psychiatry
. 2000 Jul-Sep;42(3):280–290.

RISPERIDONE VERSUS HALOPERIDOL IN ACUTE AND TRANSIENT PSYCHOTIC DISORDER

Bijoy Pratim Chaudhuri *,*, Dipesh Bhagabati †, Dipanjali Medhi ‡
PMCID: PMC2958353  PMID: 21407958

Abstract

The mechanism of action of a relatively new antipsychotic drug-Risperidone differs from conventional antipsychotics like Haloperidol. We compared low dosages of Risperidone with near equivalent dosages of Haloperidol in first episode drug naive Acute and Transient Psychotic disorder. A single blind randomised four-week study protocol was employed. Highly significant and comparable efficacy as assessed by Brief Psychiatric Rating Scale and Global Assessment of Functioning Scale was seen at the end of the Study protocol in both the groups. Risperidone had significantly, an early onset of action on some of the positive as well as negative symptoms with less incidence of Extrapyramidal Symptoms in comparison to Haloperidol. We conclude that Risperidone may represent a potential useful first line agent in the treatment of Acute and Transient Psychotic Disorder.

Keywords: Risperidone in first episode psychosis, risperidone, haloperidol, acute and transient psychotic disorder

Full Text

The Full Text of this article is available as a PDF (436.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abel K. M., O'Keane V., Murray R. M., Cleare A. J. Serotonergic function and negative and depressive symptomatology in schizophrenia and major depression. Psychoneuroendocrinology. 1997 Oct;22(7):539–548. doi: 10.1016/s0306-4530(97)00050-4. [DOI] [PubMed] [Google Scholar]
  2. Adityanjee, Pelonero A. L. Prescribing risperidone. Psychiatr Serv. 1995 Mar;46(3):291–292. doi: 10.1176/ps.46.3.291a. [DOI] [PubMed] [Google Scholar]
  3. Anderson W. H., Kuehnle J. C., Catanzano D. M. Rapid treatment of acute psychosis. Am J Psychiatry. 1976 Sep;133(9):1076–1078. doi: 10.1176/ajp.133.9.1076. [DOI] [PubMed] [Google Scholar]
  4. Buckley P. F. New dimensions in the pharmacologic treatment of schizophrenia and related psychoses. J Clin Pharmacol. 1997 May;37(5):363–378. doi: 10.1002/j.1552-4604.1997.tb04314.x. [DOI] [PubMed] [Google Scholar]
  5. Czobor P., Volavka J., Meibach R. C. Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol. 1995 Aug;15(4):243–249. doi: 10.1097/00004714-199508000-00002. [DOI] [PubMed] [Google Scholar]
  6. DANIK J. J., GOVERDHAM M. HALOPERIDOL IN THE TREATMENT OF 120 PSYCHOTIC PATIENTS. Am J Psychiatry. 1963 Oct;120:389–391. doi: 10.1176/ajp.120.4.389. [DOI] [PubMed] [Google Scholar]
  7. Daradkeh T. K., Reda F., Karim L. Efficacy and safety of risperidone in psychotic patients: an open study. J Int Med Res. 1996 May-Jun;24(3):291–295. doi: 10.1177/030006059602400309. [DOI] [PubMed] [Google Scholar]
  8. Grant S., Fitton A. Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs. 1994 Aug;48(2):253–273. doi: 10.2165/00003495-199448020-00009. [DOI] [PubMed] [Google Scholar]
  9. Janssen P. A., Niemegeers C. J., Awouters F., Schellekens K. H., Megens A. A., Meert T. F. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther. 1988 Feb;244(2):685–693. [PubMed] [Google Scholar]
  10. Kane J. M. Risperidone. Am J Psychiatry. 1994 Jun;151(6):802–803. doi: 10.1176/ajp.151.6.802. [DOI] [PubMed] [Google Scholar]
  11. Leysen J. E., Gommeren W., Eens A., de Chaffoy de Courcelles D., Stoof J. C., Janssen P. A. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther. 1988 Nov;247(2):661–670. [PubMed] [Google Scholar]
  12. Lieberman J., Jody D., Geisler S., Alvir J., Loebel A., Szymanski S., Woerner M., Borenstein M. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry. 1993 May;50(5):369–376. doi: 10.1001/archpsyc.1993.01820170047006. [DOI] [PubMed] [Google Scholar]
  13. McEvoy J. P., Hogarty G. E., Steingard S. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry. 1991 Aug;48(8):739–745. doi: 10.1001/archpsyc.1991.01810320063009. [DOI] [PubMed] [Google Scholar]
  14. Min S. K., Rhee C. S., Kim C. E., Kang D. Y. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial. Yonsei Med J. 1993 Jun;34(2):179–190. doi: 10.3349/ymj.1993.34.2.179. [DOI] [PubMed] [Google Scholar]
  15. Owens D. G. Extrapyramidal side effects and tolerability of risperidone: a review. J Clin Psychiatry. 1994 May;55 (Suppl):29–35. [PubMed] [Google Scholar]
  16. Umbricht D., Kane J. M. Risperidone: efficacy and safety. Schizophr Bull. 1995;21(4):593–606. doi: 10.1093/schbul/21.4.593. [DOI] [PubMed] [Google Scholar]

Articles from Indian Journal of Psychiatry are provided here courtesy of Wolters Kluwer -- Medknow Publications

RESOURCES